MX343689B - Formulaciones combinadas de darunavir. - Google Patents

Formulaciones combinadas de darunavir.

Info

Publication number
MX343689B
MX343689B MX2013015199A MX2013015199A MX343689B MX 343689 B MX343689 B MX 343689B MX 2013015199 A MX2013015199 A MX 2013015199A MX 2013015199 A MX2013015199 A MX 2013015199A MX 343689 B MX343689 B MX 343689B
Authority
MX
Mexico
Prior art keywords
darunavir
combination formulations
formulations
combination
solvate
Prior art date
Application number
MX2013015199A
Other languages
English (en)
Other versions
MX2013015199A (es
Inventor
Eugeen Maria Jozef Jans
Philip Erna H Heyns
Roel Jos M Mertens
Der Avoort Geert Van
Urbain Alfons C Delaet
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013015199A publication Critical patent/MX2013015199A/es
Publication of MX343689B publication Critical patent/MX343689B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a formas sólidas de dosificación oral del inhibidor de VIH darunavir y/o una sal o solvato farmacéuticamente aceptable del mismo, y formulaciones de combinación de las mismas.
MX2013015199A 2011-07-07 2012-07-06 Formulaciones combinadas de darunavir. MX343689B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (2)

Publication Number Publication Date
MX2013015199A MX2013015199A (es) 2014-09-01
MX343689B true MX343689B (es) 2016-11-16

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015199A MX343689B (es) 2011-07-07 2012-07-06 Formulaciones combinadas de darunavir.

Country Status (23)

Country Link
US (3) US20140142070A1 (es)
EP (1) EP2729130B1 (es)
JP (1) JP6122427B2 (es)
KR (1) KR102058097B1 (es)
CN (1) CN103826616B (es)
AU (1) AU2012280198B2 (es)
BR (1) BR112014000290B1 (es)
CA (1) CA2838659C (es)
CY (1) CY1121999T1 (es)
DK (1) DK2729130T3 (es)
EA (1) EA026587B1 (es)
ES (1) ES2651212T3 (es)
HR (1) HRP20171889T1 (es)
HU (1) HUE035241T2 (es)
IL (1) IL229933A (es)
LT (1) LT2729130T (es)
MX (1) MX343689B (es)
NO (1) NO2729130T3 (es)
PL (1) PL2729130T3 (es)
PT (1) PT2729130T (es)
RS (1) RS56667B1 (es)
SI (1) SI2729130T1 (es)
WO (1) WO2013004818A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
WO2013130766A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
EP3496710A4 (en) * 2016-08-08 2020-03-18 Hetero Labs Limited TABLET COMPOSITION WITH A HIGH ACTIVE SUBSTANCE LOAD FOR TREATING HIV
WO2018029565A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
EP3518935A1 (en) * 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
BR112020000842A2 (pt) 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
NZ536497A (en) 2002-05-16 2006-08-31 Tibotec Pharm Ltd Pseudopolymorphic forms of a HIV protease inhibitor and their use as a medicament
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2653940C (en) 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
PT2487163T (pt) 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
RU2010102067A (ru) 2007-06-25 2011-07-27 Тиботек Фармасьютикалз (Ie) Комбинированные композиции, включающие дарунавир и этравирин
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
UA103468C2 (ru) 2007-11-20 2013-10-25 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
AU2010210598B2 (en) * 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
PT2477992T (pt) * 2009-09-17 2017-03-20 Mylan Laboratories Ltd Processos para a preparação de darunavir e a forma amorfa do mesmo
ES2699183T3 (es) 2010-05-10 2019-02-07 Hetero Research Foundation Composiciones de darunavir
CA2837539C (en) 2011-07-07 2021-08-10 Janssen R&D Ireland Darunavir formulations
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2015373104B2 (en) 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Also Published As

Publication number Publication date
MX2013015199A (es) 2014-09-01
NO2729130T3 (es) 2018-02-03
EP2729130A1 (en) 2014-05-14
AU2012280198A8 (en) 2014-01-16
US20230302024A1 (en) 2023-09-28
US20140142070A1 (en) 2014-05-22
CN103826616B (zh) 2016-08-10
BR112014000290A2 (pt) 2017-02-07
JP2014520787A (ja) 2014-08-25
EA201490222A1 (ru) 2014-04-30
IL229933A (en) 2017-09-28
HUE035241T2 (en) 2018-05-02
DK2729130T3 (en) 2017-12-11
JP6122427B2 (ja) 2017-04-26
KR102058097B1 (ko) 2019-12-20
US20200093840A1 (en) 2020-03-26
PL2729130T3 (pl) 2018-02-28
US11654150B2 (en) 2023-05-23
ES2651212T3 (es) 2018-01-25
PT2729130T (pt) 2017-12-13
CA2838659A1 (en) 2013-01-10
EA026587B1 (ru) 2017-04-28
AU2012280198B2 (en) 2016-12-22
EP2729130B1 (en) 2017-09-06
AU2012280198A1 (en) 2014-01-09
KR20140068845A (ko) 2014-06-09
HRP20171889T1 (hr) 2018-01-12
LT2729130T (lt) 2018-01-10
BR112014000290B1 (pt) 2022-05-10
CA2838659C (en) 2020-02-18
SI2729130T1 (en) 2018-03-30
WO2013004818A1 (en) 2013-01-10
CY1121999T1 (el) 2020-07-31
RS56667B1 (sr) 2018-03-30
CN103826616A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
MX343689B (es) Formulaciones combinadas de darunavir.
MX341976B (es) Formulaciones de darunavir.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP3256149A4 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX348823B (es) Formulaciones estables de linaclotida.
MY187718A (en) Pharmaceutical formulations
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
IN2014DN10670A (es)
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP3402488A4 (en) SOLID ORAL PHARMACEUTICAL FORMS OF ESLICARBAZEPINE
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2013008559A (es) Derivados de leptina.
MX2011009844A (es) Composicion farmaceutica que comprende alisquireno.
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: GILEAD SCIENCES, INC.

FG Grant or registration